Drug intelligence / Profile preview

TCellMune-RDTB

Development stage: Preclinical
Lead developer: Vaxxit
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics

Overview

**TCellMune-RDTB** is a Vaxxit preclinical replication-defective herpes simplex virus type 1 vector vaccine candidate intended to generate protective immune responses against herpes simplex virus infection and tuberculosis. It is part of Vaxxit's HerpesVaxTat vaccine program, which uses attenuated or replication-defective HSV-1 vectors and is designed to promote durable cellular CD8 T-cell and humoral immune responses against intracellular pathogens. The precise antigen composition of the TCellMune-RDTB construct has not been publicly detailed. ([vaxxit.com](https://www.vaxxit.com/vaccines-hsv/))

Other names: TCellMune RDTB

Targets

MYH9 (Non-muscle myosin IIA)

Beyond the preview

Go deeper on TCellMune-RDTB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TCellMune-RDTB.

Explore the full profile